42% of American adults are obese, which often leads to type 2 diabetes, hypertension, and dyslipidemia. This course explores tirzepatide’s place in therapy to address this national epidemic.

Upon successful completion of this application-based course, participants should be able to:
1. Summarize current obesity management strategies and the American Association of Clinical Endocrinology’s clinical practice guideline for obesity
2. Explain the mechanism of action of tirzepatide for weight loss
3. Assess the results of the SURMOUNT-1 trial
4. Discuss the role of tirzepatide as a treatment for weight loss
5. Apply clinical implications of the SURMOUNT-1 trial to an obese patient case 

Joseph Berendse, PharmD, BCPS, BCACP
Assistant Professor
South Dakota State University

Joseph Berendse has no relevant financial relationships with ineligible companies to disclose. 

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read the article cited below.

Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med 2022; 387:205-216. https://DOI: 10.1056/NEJMoa2206038

*CEimpact provides you with two (2) opportunities to complete the exam. If there are two failed attempts, the participant will not receive CPE credit.

This course is included in our Pharmacist Membership. To get more courses like this sent to you every month, sign-up!

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: February 8, 2023
Planned Expiration Date: February 8, 2026 

Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

RV1-10.23